Charles Schwab Investment Management Inc Rapt Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 235,656 shares of RAPT stock, worth $718,750. This represents 0.0% of its overall portfolio holdings.
Number of Shares
235,656
Previous 234,439
0.52%
Holding current value
$718,750
Previous $5.83 Million
63.67%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding RAPT
# of Institutions
148Shares Held
29.2MCall Options Held
709KPut Options Held
1.06M-
Column Group LLC San Francisco, CA2.68MShares$8.18 Million15.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.49MShares$7.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.47MShares$7.54 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.03MShares$6.19 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.91MShares$5.81 Million0.0% of portfolio
About RAPT Therapeutics, Inc.
- Ticker RAPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,656,600
- Market Cap $90.5M
- Description
- RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...